plb1004
Small moleculeexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Aug 25, 2020 (NCT05347628)
Timeline
Indications
Studied for
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285148 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2026 | Avistone Biotechnology Co., Ltd., Beijing Pearl Biotechnology Limited Liability Company |
| NCT07063329 | Phase 1/Phase 2 (Phase 2) | Aug 8, 2025 | Avistone Pharmaceutical（Ningbo）Co., LTD., Jiao Tong University |
| NCT06970782 | Phase 3 | May 15, 2025 | Avistone Biotechnology Co., Ltd. |
| NCT06574347 | Phase 2 | Aug 7, 2024 | Avistone Biotechnology Co., Ltd., Shantou University |
| NCT06281964 | Phase 3 | Mar 30, 2024 | Avistone Biotechnology Co., Ltd. |
| NCT06046495 | Phase 1 | Nov 29, 2023 | Avistone Biotechnology Co., Ltd. |
| NCT06015503 | Phase 2 | Jul 21, 2023 | Avistone Biotechnology Co., Ltd., Shantou University |
| NCT06343064 | Phase 1/Phase 2 (Phase 2) | Jun 13, 2023 | Avistone Biotechnology Co., Ltd. |
| NCT05347628 | Phase 1 | Aug 25, 2020 | Avistone Biotechnology Co., Ltd., Shantou University |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avistone Biotechnology Co., Ltd. | For profit | 8 | 7 | 3 | 2020 |
| Shantou University | Academic/Hospital | 3 | 0 | 2 | 2020 |
| Avistone Pharmaceutical（Ningbo）Co., LTD. | For profit | 1 | 1 | 1 | 2025 |
| Beijing Pearl Biotechnology Limited Liability Company | Government | 1 | 1 | 1 | 2026 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1